Want to see AU:NC6 full AI Analyst Report?
Top Page
Nanollose Ltd.
(Sydney:NC6)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.08
▲(56.00% Upside)
Action:Reiterated
Date:09/06/26
The score is held back primarily by weak financial performance—persistent losses, ongoing cash burn, and a recent collapse in revenue—despite the benefit of low debt. Technicals provide a partial offset, with the price above key moving averages and positive momentum indicators, but valuation remains unattractive/unclear due to a negative P/E and no dividend yield data.
Positive Factors
Low Leverage
Very low debt relative to equity limits lender-driven solvency pressure and reduces interest-related constraints on operations. This gives Nanollose more financial flexibility than a similarly loss-making company, although equity volatility still indicates reliance on funding actions.
Negative Factors
Persistent Losses
Recurring losses across all reported periods show that the business has not yet established sustainable profitability. Negative EBIT and EBITDA weaken internal funding capacity, making continued product development and commercial expansion more dependent on external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low debt relative to equity limits lender-driven solvency pressure and reduces interest-related constraints on operations. This gives Nanollose more financial flexibility than a similarly loss-making company, although equity volatility still indicates reliance on funding actions.
Read all positive factors
Nanollose Ltd. (NC6) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$32.31M
Dividend YieldN/A
Average Volume (3M)101.17K
Price to Earnings (P/E)―
Beta (1Y)-0.27
Revenue GrowthN/A
EPS Growth-5.88%
CountryAU
Employees1
SectorConsumer Cyclical
Sector Strength84
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding409,326,900
10 Day Avg. Volume97,124
30 Day Avg. Volume101,173
Financial Highlights & Ratios
PEG Ratio-1.60
Price to Book (P/B)13.94
Price to Sales (P/S)0.00
P/FCF Ratio-9.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nanollose Ltd. Business Overview & Revenue Model
Company Description
Nanollose Limited is an Australian biomaterials enterprise dedicated to the research, development, and commercialization of microbial nanocellulose technology. Its product line features Nullarbor Fibre, an innovative lyocell fibre produced without...
How the Company Makes Money
null...
Nanollose Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 12.50K | 412.16K | 224.61K |
| Gross Profit | -14.57K | -35.83K | -779.20K | 58.29K | -223.55K |
| EBITDA | -2.68M | -1.59M | -1.10M | -1.16M | -1.51M |
| Net Income | -2.39M | -1.43M | -1.16M | -1.35M | -1.57M |
Balance Sheet | |||||
| Total Assets | 1.42M | 747.79K | 241.95K | 633.24K | 1.91M |
| Cash, Cash Equivalents and Short-Term Investments | 1.33M | 617.32K | 138.75K | 548.25K | 1.59M |
| Total Debt | 7.17K | 13.09K | 42.53K | 11.52K | 38.09K |
| Total Liabilities | 225.40K | 351.38K | 465.64K | 181.61K | 181.51K |
| Stockholders Equity | 1.20M | 396.41K | -223.69K | 451.63K | 1.73M |
Cash Flow | |||||
| Free Cash Flow | -1.80M | -1.10M | -900.95K | -1.01M | -1.39M |
| Operating Cash Flow | -1.80M | -1.10M | -900.95K | -1.01M | -1.38M |
| Investing Cash Flow | 0.00 | 0.00 | 15.97K | 0.00 | -5.35K |
| Financing Cash Flow | 2.51M | 1.58M | 475.49K | -26.57K | -32.69K |
Nanollose Ltd. Technical Analysis
Positive
0.05
Price Trends
0.07
Positive
0.07
Positive
0.07
Positive
Market Momentum
<0.01
Negative
59.83
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NC6, the sentiment is Positive. The current price of 0.05 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.83 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NC6.
Nanollose Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
54 Neutral | AU$81.14M | -21.00 | -211.39% | ― | -46.59% | 9.09% | |
49 Neutral | AU$196.08M | -13.58 | -36.83% | ― | 51.07% | -47.63% | |
47 Neutral | AU$32.31M | -10.83 | -465.54% | ― | ― | -5.88% | |
47 Neutral | AU$57.47M | -0.65 | -118.74% | ― | 499.47% | 31.20% | |
44 Neutral | AU$68.46M | -17.50 | -71.28% | ― | -51.74% | 32.00% | |
43 Neutral | AU$5.44M | -1.02 | -52.04% | ― | 32.22% | -26.53% |
* Consumer Cyclical Sector Average
AU:NC6
Nanollose Ltd.
0.08
0.02
25.40%
AU:OCC
Orthocell Ltd
0.72
-0.47
-39.50%
AU:TRP
Tissue Repair Ltd
0.09
-0.19
-67.86%
AU:ADO
AnteoTech Ltd
0.02
>-0.01
-8.70%
AU:AVE
Avecho Biotechnology Limited
0.02
0.01
110.00%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.12
-85.00%
Nanollose Ltd. Corporate Events
Nanollose seeks ASX quotation for 300,000 new shares
Sep 4, 2026
Nanollose Limited has applied for quotation of 300,000 new ordinary fully paid shares on the ASX under code NC6, with an issue date of 4 September 2026. The modest increase in quoted securities signals a small capital or equity adjustment that mar...
Nanollose widens annual loss but boosts net tangible assets
Aug 31, 2026
Nanollose Limited reported a net loss after tax of $2.39 million for the year ended 30 June 2026, a 68% increase from the prior year’s loss of $1.43 million, while revenue from ordinary activities remained at nil.The company’s net tang...
Nanollose Issues 3 Million Unquoted Employee Options Under Incentive Scheme
Aug 20, 2026
Nanollose Limited has notified the market of the issue of 3,000,000 unquoted employee options under its incentive scheme. The options, in three tranches of 1,000,000 each, were issued on August 21, 2026 and are subject to transfer restrictions, me...
Nanollose Streamlines Scale-Up with Single Pilot Facility to Accelerate Commercial Partnerships
Aug 20, 2026
Nanollose Ltd. is an advanced biomaterials company focused on scaling technology that converts microbial cellulose into fibres, fabrics and other materials for industrial use. Rather than investing in full-scale manufacturing, the company aims to ...
Nanollose Adds New Shares to ASX Quotation After Option Conversions
Aug 18, 2026
Nanollose Ltd. has lodged an application with the ASX for quotation of 2,544 new ordinary fully paid shares under its NC6 ticker. The shares, issued on 18 August 2026 following the exercise or conversion of existing options or other convertible se...
Nanollose Seeks ASX Quotation for Additional 70,000 Shares
Aug 18, 2026
Nanollose Ltd. has applied for quotation of an additional 70,000 ordinary fully paid shares on the ASX, with an issue date of 18 August 2026. The modest increase in quoted securities slightly expands the company’s free float and may improve ...
Nanollose Accelerates Onshore Pilot Build-Out as Efficiency Gains and Brand Interest Grow
Jul 30, 2026
Nanollose has moved to onshore its core production, analytics and testing capabilities to Western Australia, ordering key lab equipment and beginning site selection for a larger, fit-for-purpose facility to house a pilot plant for microbial cellul...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.